Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer

被引:36
作者
Wang, Keshan [1 ]
Ruan, Hailong [1 ]
Xu, Tianbo [1 ]
Liu, Lei [1 ]
Liu, Di [1 ]
Yang, Hongmei [2 ]
Zhang, Xiaoping [1 ]
Chen, Ke [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Dept Urol, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan 430030, Hubei, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2018年 / 11卷
基金
中国国家自然科学基金;
关键词
CRPC; androgen receptor; tumor immunity; mechanism; therapy; ANDROGEN RECEPTOR ACTIVATION; DOUBLE-BLIND; ENZALUTAMIDE MDV3100; ABIRATERONE ACETATE; CHEMOKINE RECEPTOR; CELL-PROLIFERATION; SURVIVAL ANALYSIS; PHASE-III; KAPPA-B; EXPRESSION;
D O I
10.2147/OTT.S159777
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the researches in the mechanism of CRPC and therapy for CRPC, more and more landmark progress has been made in recent years. Methods: A number of clinical and experimental studies were reviewed to indicate the novel advancement in the progressive mechanism and therapy of CRPC. Results: The androgen receptor (AR) is still a vital driver in the progression of CRPC, while other multiple mechanisms also contribute to this progression, such as tumor immunity, cancer stem cells, epithelial-mesenchymal transition and DNA repair disorder. In terms of the therapeutic methods of CRPC, chemotherapy with drugs, such as docetaxel, has been the first-line therapy for CRPC for many years. Besides, newer agents, which target some of the above mechanisms, show additional overall survival benefits for CRPC patients. These therapies include drugs targeting the androgen axis pathway (androgen synthesis, androgen receptor splice variants, coactivators of AR and so on), PI3K-AKT pathway, WNT pathway, DNA repair, rearrangement of ETS gene, novel chemotherapy and immunotherapy, bone metastasis therapy and so on. Understanding these novel findings on the mechanisms of CRPC and the latest potential CRPC therapies will direct us for further exploration of CRPC. Conclusion: Through comprehensive consideration, the predominant mechanism of CRPC might be the AR signal axis concomitant with tumor microenvironment, stress, immunity, tumor microenvironment and so on. For CRPC therapy, targeting the AR axis pathway and chemotherapy are the first-line treatments at present. However, with the advancements in CRPC therapy made by the researchers, other novel potential methods will occupy more and more important position in the treatment of CRPC, especially the therapies targeting the tumor microenviroment, tumor immunity and DNA repair and so on.
引用
收藏
页码:3167 / 3178
页数:12
相关论文
共 121 条
  • [1] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
    Andersen, Raymond J.
    Mawji, Nasrin R.
    Wang, Jun
    Wang, Gang
    Haile, Simon
    Myung, Jae-Kyung
    Watt, Kate
    Tam, Teresa
    Yang, Yu Chi
    Banuelos, Carmen A.
    Williams, David E.
    McEwan, Iain J.
    Wang, Yuzhou
    Sadar, Marianne D.
    [J]. CANCER CELL, 2010, 17 (06) : 535 - 546
  • [2] Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer
    Antonarakis, Emmanuel S.
    [J]. ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (04) : 520 - 521
  • [3] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
    Arora, Vivek K.
    Schenkein, Emily
    Murali, Rajmohan
    Subudhi, Sumit K.
    Wongvipat, John
    Balbas, Minna D.
    Shah, Neel
    Cai, Ling
    Efstathiou, Eleni
    Logothetis, Chris
    Zheng, Deyou
    Sawyers, Charles L.
    [J]. CELL, 2013, 155 (06) : 1309 - 1322
  • [4] Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel
    Arsov, Christian
    Winter, Christian
    Rabenalt, Robert
    Albers, Peter
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (06) : 762 - 771
  • [5] Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
    Ayer Botrel, Tobias Engel
    Clark, Otovio
    Lima Pompeo, Antonio Carlos
    Horta Bretas, Francisco Flavio
    Sadi, Marcus Vinicius
    Ferreira, Ubirajara
    dos Reis, Rodolfo Borges
    [J]. PLOS ONE, 2016, 11 (06):
  • [6] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    [J]. EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [7] Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment
    Badrising, Sushil
    van der Noort, Vincent
    van Oort, Inge M.
    van den Berg, H. Pieter
    Los, Maartje
    Hamberg, Paul
    Coenen, Jules L.
    van den Eertwegh, Alfons J. M.
    de Jong, Igle J.
    Kerver, Emile D.
    van Tinteren, Harm
    Bergman, Andries M.
    [J]. CANCER, 2014, 120 (07) : 968 - 975
  • [8] Overcoming mutation-based resistance to antiandrogens with rational drug design
    Balbas, Minna D.
    Evans, Michael J.
    Hosfield, David J.
    Wongvipat, John
    Arora, Vivek K.
    Watson, Philip A.
    Chen, Yu
    Greene, Geoffrey L.
    Shen, Yang
    Sawyers, Charles L.
    [J]. ELIFE, 2013, 2
  • [9] Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
    Banuelos, Carmen A.
    Lal, Aaron
    Tien, Amy H.
    Shah, Neel
    Yang, Yu Chi
    Mawji, Nasrin R.
    Meimetis, Labros G.
    Park, Jacob
    Kunzhong, Jian
    Andersen, Raymond J.
    Sadar, Marianne D.
    [J]. PLOS ONE, 2014, 9 (09):
  • [10] Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer
    Baylot, Virginie
    Katsogiannou, Maria
    Andrieu, Claudia
    Taieb, David
    Acunzo, Julie
    Giusiano, Sophie
    Fazli, Ladan
    Gleave, Martin
    Garrido, Carmen
    Rocchi, Palma
    [J]. MOLECULAR THERAPY, 2012, 20 (12) : 2244 - 2256